EGFR and head and neck squamous cell carcinoma: Cetuximab-IR700 (RM-1929), targeting epidermal growth factor receptor (EGFR), is now being evaluated for the treatment of inoperable head and neck squamous cell cancer (HNSCC) in a global phase III clinical trial [38].